• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconBioNTech

BioNTech

Page 4 of 6
NewslettersCrypto creeps lower, global stocks rally as investors place fresh bets on the recovery trade
By Bernhard WarnerAugust 24, 2021
HealthFDA to green-light a third COVID shot for those with compromised immune system
By Robert Langreth, Josh Wingrove and BloombergAugust 12, 2021
NewslettersStocks, crypto and commodities are quiet—but another potential inflation jolt looms for investors
By Bernhard WarnerAugust 12, 2021
NewslettersThe crypto rally rages on as bulls push Bitcoin above $46,000
By Bernhard WarnerAugust 10, 2021
HealthPfizer partner to test COVID vaccine targeting Delta variant this month
By Christiaan Hetzner and Christiaan HetznerAugust 9, 2021
CYPRUS-HEALTH-VIRUS-VACCINE
HealthNovavax shares pop after clinching COVID vaccine supply deal with European Union
By Sophie MellorAugust 5, 2021
HealthBioNTech plans on developing a vaccine that prevents Malaria
By Naomi Kresge and BloombergJuly 26, 2021
HealthCountries eye booster shots as the delta variant evades less effective COVID vaccines
By BloombergJuly 10, 2021
HealthThe kids are (not) alright: Europe sounds the alarm as Delta variant soars among teens and 20-somethings
By Ian Mount, Bernhard Warner and Katherine DunnJuly 8, 2021
HealthDelta variant surges in Midwest as Trump Country rejects vaccines
By Josh Wingrove and BloombergJuly 7, 2021
HealthIsrael data reportedly shows drop in efficacy of Pfizer-BioNTech vaccine as delta variant spreads
By Alisa Odenheimer and BloombergJuly 5, 2021
HealthOperation Overtake: How Europe surpassed the U.S. in its COVID vaccination push
By Ian Mount, Vivienne Walt, David Meyer and Bernhard WarnerJuly 1, 2021
HealthJohnson & Johnson one-shot COVID jab wins U.K. approval
By Suzi Ring and BloombergMay 28, 2021
HealthModerna COVID vaccine up to 100% effective in teens
By Robert Langreth and BloombergMay 25, 2021
An employee checks bottles of diluent inside the pharmaceutical plant Fareva in Poce-sur-Cisse, Central France, on April 22, 2021. Fareva was chosen as the main supplier of the candidate RNA messenger vaccine from the German company CureVac. The site will therefore produce the diluent used in this vaccine.
HealthThese four COVID-19 vaccines could soon join the pandemic fight
By David MeyerMay 8, 2021
1
  • 2
  • 3
  • 4
  • 5
  • 6
6
Most Popular
Middle East
Iran is now on 'death ground' amid existential threat from U.S. attacks and could 'go big' in retaliation, former NATO commander warnsAn image of a popular article
By Jason MaFebruary 28, 2026
Economy
Your grandparents are the reason the U.S. isn't in a recession right now. That won't last foreverAn image of a popular article
By Eleanor PringleMarch 1, 2026
Success
Japanese companies are paying older workers to sit by a window and do nothing—while Western CEOs demand super-AI productivity just to keep your jobAn image of a popular article
By Orianna Rosa RoyleFebruary 27, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.